Results 161 to 170 of about 3,726 (180)

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study

Journal of Dermatology, 2018
Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima   +2 more
exaly  

Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis

Journal of Pharmaceutical and Biomedical Analysis, 2020
Nathalie Van den Berghe, Aurélie Truffot, Miet Peeters   +2 more
exaly  

Apremilast/guselkumab

Reactions Weekly, 2022
openaire   +1 more source

Brodalumab/guselkumab

Reactions Weekly, 2021
openaire   +1 more source

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Journal of Clinical Medicine, 2020
Marco Galluzzo, Lorenzo Tófani, Paolo Lombardo   +2 more
exaly  

<p>Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</p>

Drug Design, Development and Therapy, 2019
Eric J Yang, Mary Patricia Smith, Karen Ly   +2 more
exaly  

Belimumab/guselkumab

Reactions Weekly, 2020
openaire   +1 more source

Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

Journal of Psoriasis and Psoriatic Arthritis, 2019
Chris Cameron, Cheryl Druchok, Brian Hutton   +2 more
exaly  

Guselkumab (Tremfya) for Psoriasis

JAMA, 2017
openaire   +2 more sources

Guselkumab/secukinumab/ustekinumab

Reactions Weekly, 2022
openaire   +1 more source